Dişel, UmutKöse, FatihBilici, AhmetÖzgüroğlu, MustafaSağlam, SezerŞeker, MesutAksoy, SercanTek, İbrahimMandel, Nil MolinasDemir, GökhanArslan, ÇağatayDemiray, MutluÖztürk, Mehmet AkifSalepçi, TaflanEralp, YeşimSelçukbiricik, FatihTemizaş, GökçeFidan, Ebru Gül2022-09-152022-09-152022Dişel, U., Köse, F., Bilici, A., Özgüroğlu, M., Sağlam, S., Şeker, M. ... Fidan, E. G. (2022). The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors. Journal of Oncological Science, 8(2), 87-93. https://doi.org/10.37047/jos.2022-893102651-45322452-3364https://doi.org/10.37047/jos.2022-89310https://hdl.handle.net/20.500.12511/9715Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact of CGP on the treatment plan and outcomes in a significant number of patients. Material and Methods: We carried out a retrospective case-control study on 164 adult patients with advanced solid tumors from 15 oncology centers in Türkiye. Results: In all cases, CGP was performed within 23.8 [standard deviation (SD)±32.1] months of initial diagnosis. Non-small cell lung carcinoma, breast cancer, unknown primary carcinoma, colorectal carcinoma, and sarcoma were among the most common tumor types, accounting for 61.5% of all cases. CGP was performed immediately after the diagnosis of advanced cancer in 13 patients (7.9%). In 158 patients (96.4%), at least one GA was found as per the CGP report. Also, in the reports, the average tumor mutational burden (TMB) and GAs were 7.3 (SD±8.7) mut/Mb and 3.5 (SD±2.0), respectively. According to CGP reports, 58 patients had 79 evidence-based drug suggestions for their particular tumor type, whereas 97 patients had 153 evidence-based drug suggestions for another tumor type. After the primary oncologist interpreted the CGP reports, significant changes were made to the treatment of 35 (21.3%) patients. Conclusion: We strongly believe that in the future, high-TMB or other tumor-agnostic biomarkers will become much more afford-able, and CGP will serve as one of the major decision-making tools for the treatment of patients along with pathological, radiological or lab-oratory tests.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessComprehensive Genomic HybridizationGenomicsNeoplasmsRetrospective StudiesArticle82879310.37047/jos.2022-893102-s2.0-85136777670Q4